Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bendamustine + etoposide + cytarabine + melphalan
- Development stage
- Unknown
- Lead developer
- Jenapharm
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of bendamustine, etoposide, cytarabine (also known as ARA-C), and melphalan. It is primarily used as a high-dose conditioning regimen before autologous stem cell transplantation in patients with resistant or relapsed lymphoma, particularly non-Hodgkin lymphoma. - Bendamustine is an alkylating agent that causes DNA crosslinking and strand breaks. - Etoposide inhibits topoisomerase II, leading to DNA damage and apoptosis. - Cytarabine is an antimetabolite that inhibits DNA synthesis by acting as a cytidine analog. - Melphalan is another alkylating agent that crosslinks DNA and prevents replication. The combination aims to maximize anti-tumor efficacy through multiple mechanisms of action targeting rapidly dividing malignant cells[1][2][3][4][5].
- Other names
- BeEAMBenda-EAM
02
Targets
DNA polymerase familyDNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on bendamustine + etoposide + cytarabine + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bendamustine + etoposide + cytarabine + melphalan.